What's new

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised

Jun 10, 2025 - 13:45
 0
Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

The uncertain future of gun violence research and prevention

Next Article

Annual reports and work programmes

Related Posts

Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Date of authorisation: 24/04/2008, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 4, 2025  0

Management Board meeting: 13 March 2025, European Medicines Agency, Amsterdam, the Netherlands, 13 March 2025

Management Board meeting: 13 March 2025, European Medic...

May 23, 2025  0